{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:04:26Z","timestamp":1700611466842},"reference-count":60,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,3,7]],"date-time":"2011-03-07T00:00:00Z","timestamp":1299456000000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In recent years, many studies have confirmed that allogeneic stem cell transplantation (allo\u2010SCT) can provide long\u2010term disease control and possible cure in selected patients with chronic lymphocytic leukaemia (CLL), including those with a biologically highly unfavourable risk profile. A retrospective analysis of allo\u2010SCT in 30 patients with CLL whose risk profile was unfavourable and who were treated in the years 2000\u20132009 was performed. The aim was to compare the results of allo\u2010SCT by prognostic factors and conditioning type and evaluate the results of unrelated transplantation. The median age was 54 years. Donors were 8 HLA\u2010matched siblings and 22 unrelated volunteers, 11 of whom were mismatched. Eighteen patients were treated with reduced intensity conditioning. Twelve patients received myeloablative conditioning. Estimated overall survival (OS) at 3 years was 78%, progression\u2010free survival (PFS) 71%, relapse incidence 10% and non\u2010relapse mortality (NRM) 16%, respectively, with a median follow\u2010up of 35 months. According to molecular\/cytogenetic characteristics, OS and PFS for the high risk group (17p\u2010 or 11q\u2010) were 89 and 77%, respectively, not significantly different from those with standard risk. Graft\u2010versus\u2010host disease (GVHD) was associated with greater toxicity; significantly higher NRM for patients with aGVHD (<jats:italic>p<\/jats:italic>\u2009=\u20090.04) and worse PFS for patients with cGVHD (<jats:italic>p<\/jats:italic>\u2009=\u20090.04). Our results for the refractory disease group (77% responses) indicate that chemoresistance may be overcome by the GVL effect. Transplants from unrelated donors may be considered comparable to those from related donors. Copyright \u00a9 2010 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.949","type":"journal-article","created":{"date-parts":[[2010,6,10]],"date-time":"2010-06-10T04:18:45Z","timestamp":1276143525000},"page":"22-30","source":"Crossref","is-referenced-by-count":4,"title":["The effect of allogeneic stem cell transplantation on high risk chronic lymphocytic leukaemia: a single centre retrospective analysis"],"prefix":"10.1002","volume":"29","author":[{"given":"V","family":"V\u00e1lkov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"V\u00edtek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Markov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Pohlreich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Bene\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Michalov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Cetkovsk\u00fd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Trn\u011bn\u00fd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,3,7]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V46.2.219.219"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19871201)60:11<2712::AID-CNCR2820601122>3.0.CO;2-1"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb02969.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609054782"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1999.tb01731.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI3009"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.1023"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402339"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403707"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040857"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20132"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15260-9"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4516"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200325"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140582"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1371"},{"issue":"4","key":"e_1_2_7_20_2","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1200\/JCO.1994.12.4.748","article-title":"Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results","volume":"12","author":"Khouri IF","year":"1994","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401201"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1778"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705375"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.381"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(00)00524-5"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0298"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.2982"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4321"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0941"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06591.x"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703548"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705130"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.011"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3372"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.06.004"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.2165\/00066982-200509010-00004"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"issue":"6","key":"e_1_2_7_39_2","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka D","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90380-0"},{"issue":"5","key":"e_1_2_7_41_2","first-page":"400","article-title":"Combined molecular biological and molecular cytogenetic analysis of genomic changes in 146 patients with B\u2010cell chronic lymphocytic leukemia","volume":"55","author":"Berkova A","year":"2008","journal-title":"Neoplasma"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702146"},{"issue":"2","key":"e_1_2_7_43_2","first-page":"126","article-title":"HLA\u2010DPB1 gene analysis in haematopoietic stem cell transplantations","volume":"145","author":"Vrana M","year":"2006","journal-title":"Cas Lek Cesk"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1377"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.13"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.3.756"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0654-9"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11828"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2004.06.002"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402905"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403745"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.569"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4757"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-078592"},{"key":"e_1_2_7_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404441"},{"key":"e_1_2_7_56_2","first-page":"474a","article-title":"Conventional HLA\u2010identical sibling bone marrow transplantation is able to cure chronic lymphocytic leukemia","volume":"102","author":"Michallet M","year":"2003","journal-title":"Blood"},{"key":"e_1_2_7_57_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-098483"},{"key":"e_1_2_7_58_2","doi-asserted-by":"crossref","first-page":"45a","DOI":"10.1182\/blood.V104.11.147.147","article-title":"Minimal residual disease (MRD) kinetics after autologous stem cell transplantation for chronic lymphocytic leukemia (CLL) correlate to IgVH mutational status and predict post transplant outcome: real time ASO\u2010IgH PRC results of the GCLLSG CLL3 Protocol","volume":"104","author":"Ritgen M","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_59_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.531"},{"key":"e_1_2_7_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.96"},{"key":"e_1_2_7_61_2","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2009_01_76"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.949","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T19:39:19Z","timestamp":1700595559000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.1002\/hon.949"],"URL":"https:\/\/doi.org\/10.1002\/hon.949","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}